Available Studies
ROS, MAP, MARS, Clinical Core, LATC
Categories
Pathology
As of 03/2019, this variable replaces tdp_stage4.
TDP-43 immunohistochemistry was performed on 8 brain regions using phosphorylated monoclonal TAR5P-1D3 (pS409/410; 1:100, Ascenion, Munich, Germany) TDP-43 antibody. Since 2015, this antibody has been obtained from MilliporeSigma, Burlington, MA.
Presence of TDP-43 cytoplasmic inclusions in neurons and glia are determined for each region (yes vs. no), and four stages of TDP-43 distribution are recognized:
Value | Coding | Regions (see above) |
---|---|---|
0 | None | None |
1 | Amygdala | #1 |
2 | Amygdala + Limbic | #1-4 |
3 | Amygdala + Limbic + Neocortical | #1-8 |
If creating a dichotomized version of this variable, RADC recommends the following:
Value | Coding |
---|---|
0 | No TDP-43 pathology or TDP-43 pathology in amygdala only (Stages 0 and 1) |
1 | TDP-43 pathology extending beyond amygdala (Stages 2 and 3) |
Note: The listed reference describes a 2-stage and 6-stage version of TDP-43.